They join Moderna and Pfizer in being in the final testing trials….
The Johnson & Johnson vaccine could be just one injection….
Johnson and Johnson will also look for 60,000 person trial group twice the size of the other two companies …..
The first two companies are already into their trials…
Buoyed by positive results in its earlier studies, Johnson & Johnson has begun the final stage of clinical trials for its coronavirus vaccine.
Although they started a couple of months behind the other so-called Phase 3 trials in the United States, Johnson & Johnson’s trials, which began on Monday, will be the largest, with plans to enroll 60,000 participants. And this experimental vaccine may have considerable advantages over some of its competitors, experts said. It does not need to be stored in subzero temperatures, and may require just one dose instead of two.
“It would be fabulous if we had something at a single dose,” said Dr. Judith Feinberg, the vice chairwoman for research in medicine at West Virginia University, who was not involved in the study.
Only Phase 3 trials, which compare the effects of a vaccine with those of a placebo, can determine if a single dose is indeed effective, Dr. Feinberg said. If it works, that could greatly speed efforts to curb the pandemic….
“I mean, just think about yourself — how much easier would it be for you to go to your local doctor or your local drugstore, and be once and done?” said Dr. Daniel Barouch, a virologist at Boston’s Beth Israel Deaconess Medical Center who helped develop the Johnson & Johnson vaccine….
Donald Trump is trying to beatdown the FDA to do vaccine things ‘his’ way NOT the ‘experts’ way…
President Trump said Wednesday that the White House “may or may not” approve new Food and Drug Administration guidelines requiring outside experts to weigh in before the agency approves a coronavirus vaccine, and said the plan “sounds like a political move,” undercutting government scientists who had said the opposite just hours earlier.
The president’s comments to reporters in the White House briefing room came after four of the administration’s top health officials who are helping to steer the government’s coronavirus response appeared in front of a Senate panel in an effort to bolster public trust in the F.D.A.
The officials told the panel that they had complete faith in the agency and that science and data — not politics — were guiding its decisions.
Their testimony came as the F.D.A. prepared to issue stricter guidelines for the emergency authorization of any new coronavirus vaccine. That would add a new layer to the vetting process….